{"id":19516,"date":"2015-11-04T19:45:33","date_gmt":"2015-11-04T14:15:33","guid":{"rendered":"https:\/\/cardiophile.org\/?p=19516"},"modified":"2015-11-04T19:45:33","modified_gmt":"2015-11-04T14:15:33","slug":"biologics-for-takayasu-arteritis","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/","title":{"rendered":"Biologics for Takayasu Arteritis"},"content":{"rendered":"<h2><span style=\"color: #008000;\">Biologics for Takayasu Arteritis<\/span><\/h2>\n<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/wv82ZY4YmAg\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><br \/>\nA multicentric retrospective analysis of 49 patients with Takayasu arteritis refractory to steroids or disease modifying drugs (mostly methotrexate and azathioprine) treated with biologics {tumor necrosis factor (TNF) alpha antagonists or&nbsp;tocilizumab} has been reported in&nbsp;<em>Circulation&nbsp;<\/em>[1].<\/p>\n<p>Tocilizumab is a monoclonal antibody directed against interleukin 6 (IL-6). Overall response to biologics for Takayasu arteritis was 83% at one year (either partial or complete remission). The responders had a lower initial C-reactive protein levels and lower requirement for steroids. Both C-reactive protein levels and steroid requirement decreased significantly at 12 months treatment with biologicals. The 3 year relapse free survival was 90.9% with biologically targeted therapy compared with 58.7% for disease modifying therapy. There was no difference in efficacy between TNF alpha antagonists and tocilizumab. Over a median follow up period of 2 years, about one fifth of them had adverse effects with biologically targeted therapy and 6.6% had discontinued treatment. The authors concluded that biologics for Takayasu Arteritis had high efficacy and an acceptable safety profile.<\/p>\n<p><span style=\"color: #0000ff;\"><strong>Reference<\/strong><\/span><\/p>\n<ol>\n<li>Arsene Mekinian, Clo\u00e9 Comarmond, Mathieu Resche-Rigon, Tristan Mirault, Jean Emmanuel Kahn, Marc Lambert, Jean Sibilia, Antoine N\u00e9el, Pascal Cohen, Miguel Hie, Sabine Berthier, Isabelle Marie, Christian Lavigne, Marie Anne Vandenhende, G\u00e9raldine Muller, Zahir Amoura, Herv\u00e9 Devilliers, S\u00e9bastien Abad, Mohamed Hamidou, Lo\u00efc Guillevin, Robin Dhote, Bertrand Godeau, Emmanuel Messas, Patrice Cacoub, Olivier Fain, David Saadoun, French Takayasu Network. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26354797\/\">Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients<\/a>.&nbsp;Circulation. 2015 Nov 3;132(18):1693-700.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Biologics for Takayasu Arteritis A multicentric retrospective analysis of 49 patients with Takayasu arteritis refractory to steroids or disease modifying drugs (mostly methotrexate and azathioprine) treated with biologics {tumor necrosis factor (TNF) alpha antagonists or&nbsp;tocilizumab} has been reported in&nbsp;Circulation&nbsp;[1]. Tocilizumab is a monoclonal antibody directed against interleukin 6 (IL-6). Overall response to biologics for Takayasu [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":39979,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-19516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biologics for Takayasu Arteritis - TNF\u03b1 antagonists or Tocilizumab<\/title>\n<meta name=\"description\" content=\"Study has shown that biologics for Takayasu Arteritis (TNF alpha antagonists or Tocilizumab) have high efficacy and acceptable safety profile.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biologics for Takayasu Arteritis - TNF\u03b1 antagonists or Tocilizumab\" \/>\n<meta property=\"og:description\" content=\"Study has shown that biologics for Takayasu Arteritis (TNF alpha antagonists or Tocilizumab) have high efficacy and acceptable safety profile.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-04T14:15:33+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Biologics for Takayasu Arteritis\",\"datePublished\":\"2015-11-04T14:15:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/\"},\"wordCount\":246,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/\",\"name\":\"Biologics for Takayasu Arteritis - TNF\u03b1 antagonists or Tocilizumab\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2015-11-04T14:15:33+00:00\",\"description\":\"Study has shown that biologics for Takayasu Arteritis (TNF alpha antagonists or Tocilizumab) have high efficacy and acceptable safety profile.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/biologics-for-takayasu-arteritis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biologics for Takayasu Arteritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biologics for Takayasu Arteritis - TNF\u03b1 antagonists or Tocilizumab","description":"Study has shown that biologics for Takayasu Arteritis (TNF alpha antagonists or Tocilizumab) have high efficacy and acceptable safety profile.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/","og_locale":"en_US","og_type":"article","og_title":"Biologics for Takayasu Arteritis - TNF\u03b1 antagonists or Tocilizumab","og_description":"Study has shown that biologics for Takayasu Arteritis (TNF alpha antagonists or Tocilizumab) have high efficacy and acceptable safety profile.","og_url":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2015-11-04T14:15:33+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Biologics for Takayasu Arteritis","datePublished":"2015-11-04T14:15:33+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/"},"wordCount":246,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/","url":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/","name":"Biologics for Takayasu Arteritis - TNF\u03b1 antagonists or Tocilizumab","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/#primaryimage"},"thumbnailUrl":"","datePublished":"2015-11-04T14:15:33+00:00","description":"Study has shown that biologics for Takayasu Arteritis (TNF alpha antagonists or Tocilizumab) have high efficacy and acceptable safety profile.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/biologics-for-takayasu-arteritis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Biologics for Takayasu Arteritis"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/19516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=19516"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/19516\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=19516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=19516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=19516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}